Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Launched by BELITE BIO, INC · Jul 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called tinlarebant (LBS-008) to see how well it works and how safe it is for people with Geographic Atrophy (GA), a type of eye disease that can lead to vision loss. The trial is currently looking for participants, and anyone between the ages of 21 and 85 with a confirmed diagnosis of GA may qualify. To be eligible, participants need to have specific vision levels in the eye that will be studied and must not have certain other eye conditions, like diabetic retinopathy or advanced glaucoma.

If you decide to join the trial, you will be randomly assigned to receive either the tinlarebant medication or a placebo, which is a non-active version of the treatment. Throughout the study, you will have regular check-ups to monitor your health and vision. This trial is important because it aims to find new ways to help people with GA, and your participation could contribute to better treatments for this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes.
• • Minimum BCVA is required in the study eye
• Exclusion Criteria:
• • The presence of diabetic macular edema or macular disease in either eye.
• • Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye.
• • Uncontrolled diagnosed glaucoma in the study eye